Rivet PVS Therapy in Group 2 PH-HFpEF

首次发布于 2022 年 1 月 25 日

Rivet PVS Therapy in Group 2 PH-HFpEF Canada

首次发布于 2022 年 4 月 18 日

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

计划入组 164 人 · 首次发布于 2021 年 6 月 30 日

MR antagonist (diabetic nephropathy/hypertension/heart failure )

Tovinontrine

C₂₁H₂₆N₆O₂

AAV9-tert gene therapy (pulmonary fibrosis/heart failure/aplastic anemia)

VentriPoint Diagnostics Ltd

Cardiol Therapeutics Inc

Canada

Abbott Laboratories

United States

Tenax Therapeutics Appoints Gillian Andor as VP of Clinical Operations to Bolster Phase 3 Program

Tenax Therapeutics' Phase 3 LEVEL Trial of TNX-103 Fails to Meet Primary Endpoint in PH-HFpEF

GSK Acquires 35Pharma for $950M to Advance Potential Best-in-Class Pulmonary Hypertension Treatment HS235